Benutzerspezifische Werkzeuge

Curriculum Vitae - Graeme Eisenhofer, Ph.D.

Personal Information

profeisenhofer.jpg
Business address:

Departments of Clinical Chemistry and Laboratory Medicine, University of Dresden, Fetscherstr 74, O1307 Dresden, Germany
Phone:
+ 0351 458-4595
Fax:
+ 0351 458-5887
E-Mail:
graeme.eisenhofer@uniklinikum-dresden.de
Nationaltity:
US Citizen, New Zealander by birth
Family:
Married to Kathleen; daughter, Suzanne

Education And Academic Qualifications

1975-78
 


       
Victoria University of Wellington, Wellington, New Zealand.
1977 BSc. with major in Biochemistry.
Secondary subjects: Chemistry, Mathematics and Physiology.   
1978 BSc. Honors in Biochemistry.

1979-82           



 
Wellington Clinical School of Medicine, Wellington, New Zealand,
Ph.D. in Human Physiology and Medicine awarded 1983 through the Department of Medicine, University of Otago.
Thesis: The acute and chronic effects of ethanol on water metabolism and the sympathetic nervous system in man.

Appointments

2007-pres.



Departments of Medicine and Clinical Chemistry and Laboratory Medicine, University of Dresden, Dresden, Germany.
Professor and Chief: Division of Clinical Neurochemistry

1998-2007        




 
National Institutes of Health, Bethesda, Maryland, USA.
Staff Scientist:   
<1999 Clinical Neuroscience Branch
>1999 Clinical Neurocardiology Section     
National Institute of Neurological Disorders and Stroke.

1991-1998


National Institutes of Health, Bethesda, Maryland, USA.
Head: Unit on Preclinical Neurochemistry,
Clinical Neuroscience Branch, NINDS

Awards

  • Fellowship Grant ($57,000) from the Medical Research Council of New Zealand. Project: "Effects of acute and chronic alcohol consumption on fluid balance and the sympathetic nervous system" (1982).   
  • Travel Award from the International Union of Physiological Sciences for the 1983 Triennial Congress. Nominated by the Physiological Society of New Zealand (1983).
  • Equipment Grant ($43,000) from the New Zealand Golden Kiwi Lottery Board. Project: "Measurement of catecholamines and metabolites by liquid chromatography with electrochemical detection" (1983).
  • International Research Fellowship from the United States Public Health Service. Nominated by the Medical Research Council of New Zealand. Granted 6 month extension in 1986 (1985).
  • NIH Conference Grant (R13 MH 55882) Co-writer with Dr. D. Goldstein — submitted through Dr. R. McCarty, University of Virginia — Priority score: 115 (1996).
  • Group NINDS Merit Award: For the development and promulgation of a simple and specific test for pheochromocytoma (2000).

     

Professional Society Membership (current)

  • The American Physiological Society   
  • The American Association of Clinical Chemistry

      

Teaching

  • Lecturer for Foundation for Advanced Education in the Sciences Continuing Medical Education Program: "Basic Neurochemistry (BIOC 512M)" and "Endocrine Hypertension" in the course "A Review of Endocrinology Diagnosis and Treatment."
  • Preceptor for doctoral students and postdoctoral and clinical research fellows.

     

Editing And Review

  • Coeditor of  "Catecholamines: Bridging Basic Science with Clinical Medicine" Volume 42 in the series "Advances in Pharmacology". (Eds.) Goldstein D.S., Eisenhofer G., McCarty R. Academic Press, London, 1998.
  • Guest Editor for Experimental Neurology (volume 135 No 2).
  • Coeditor of “Endocrine Hypertension” Volume 970 of “Annals of the New York Academy of Sciences”. (Eds.) Pacak K. and Eisenhofer G. New York Academy of Sciences, New York, 2002.
  • Coeditor of “Pheochromocytoma: First International Conference “Annals of the New York Academy of Sciences”. (Eds.) Pacak K. and Eisenhofer G. New York Academy of Sciences, New York, 2006.
  • Editor of the Catecholamine Club Newsletter.
  • Grant Reviews: National Institutes of Health CSR (Special Study Section, Neurological sciences subcommittee 1), Department of Veterans Affairs, National Health and Medical Research Council of Australia, New Zealand Heart Foundation, Health Research Council of New Zealand.
  • Member of the review committee for the Julius Axelrod Award in Pharmacology.
  • Manuscript Reviews (15-20 manuscripts reviewed annually).

      

Board And Orangizing Commitee Memberships

  • Co-organizer for the Eighth International Catecholamine Symposium, Asilomar, California, October 13-18, 1996 (http://www.catecholamine.org/catsymp.html)
  • Chief Operating Officer for the Foundation for Catecholamine Research, a philanthropic foundation for fostering research about catecholamine systems (http://www.catecholamine.org)
  • Scientific Advisory Board: Somerset Pharmaceuticals, Inc
  • International Organizing Committee, Ninth International Catecholamine Symposium, Kyoto, Japan, April 1- 5, 2001.
  • Principal organizer of the First International Workshop on Endocrine Hypertension, National Institutes of Health, Bethesda, Maryland, November 16, 2001.
  • Co-organizer of a Workshop on Molecular Differentiation of Benign and Malignant Pheochromocytomas and Neuroblastomas, Cold Spring Harbor, New York, November 16-18, 2003.
  • Member of the Executive Committee and Scientific co-chair: Pheochromocytoma Research Support Organization (PRESSOR http://www.pressor.org).
  • Vice-president and co-organizer of the First International Symposium on Pheochromocytoma, ISP2005 — Bethesda, Maryland, October 20-23, 2005 (http://www.pressor.org/ISP2005).
  • President of the Catecholamine Club for the 2005/2006-program year.
  • Co-organizer of a Patient-Health Professional Interactive Conference — SDHB-related Pheochromocytoma: Recent Discoveries and Current Diagnostic and Therapeutic Approaches, NIH, Bethesda, Maryland, September 29, 2006.

       

Invited Presentations

  • Invited seminar: “Acute and chronic effects of ethanol ingestion on the sympathetic nervous system,” Department of Psychiatry and the Section of Brain and Vascular Research of the Division of Medical Research, Cleveland Clinic, Cleveland, Ohio (1987).
  • Invited seminars: “Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anesthetized dog,” and “In vivo kinetics of catecholamines: recent findings and new directions,” Invited speaker at 4 German centers (Departments of Pharmacology and Toxicology at the Universities of Freiburg, Bonn, and Würzburg and the Cardiology Department, Medical School, University of Würzburg). Sponsored by the Department of Pharmacology and Toxicology, University of Freiburg, Freiburg, Germany (October, 1991).
  • Invited lecture: “Plasma levels of dihydroxyphenylalanine, dihydroxyphenylglycol and norepinephrine as markers of sympathetic function,” 7th International Catecholamine Symposium, Amsterdam, The Netherlands (June, 1992).
  • Invited seminar: “Compartmental analysis of catecholamine kinetics and metabolism: Application to studies of the sympatho-adrenal system in health and disease.” Department of Clinical Physiology, Sahlgrenska Hospital, University of Göteborg, Göteborg, Sweden (June, 1993).
  • Invited seminar: “Clinical assessment of cardiac sympathetic nerve function in health and disease,” Department of Internal Medicine, St. Radboud University Hospital, Nijmegen, The Netherlands (June, 1993)
  • Invited lecture: “In vivo kinetics of catecholamines,” 8th International Meeting on Adrenergic Mechanisms, Porto, Portugal (September, 1993).
  • Invited seminar: “The in vivo kinetics of catecholamines and metabolites for examination of sympathetic function” Department of Physiology, University of Göteborg, Göteborg, Sweden (June, 1995).
  • Clinical Center Grand rounds: “Cardiac sympathetic nerve function in congestive heart failure,” NIH, Bethesda, Maryland (1995).
  • Invited seminar: “Cardiac sympathetic nerve function in congestive heart failure,” Department of Physiology, University of Nebraska, Omaha, Nebraska (May, 1996).
  • Invited seminar: “Plasma metanephrines for diagnosis of pheochromocytoma,” Sahlgrenska Hospital, University of Göteborg, Göteborg, Sweden (June, 1996).
  • Invited lecture: “Plasma metanephrines for diagnosis of pheochromocytoma,” 10th International Congress of Endocrinology - Sponsored by Corning Hazleton (June, 1996).
  • Invited seminars: “Cardiac sympathetic nerve function in congestive heart failure” and “Plasma free metanephrines for diagnosis of pheochromocytoma,” Cardiology Seminar Series, Mount Sinai Hospital, Toronto, Canada (June, 1996).
  • Invited seminar: “Cardiac sympathetic nerve function in congestive heart failure,” Department of Pharmacology, University of Otago, Dunedin, New Zealand (August, 1996).
  • Invited lecture: “Plasma free metanephrines: a sensitive test for diagnosis of sporadic and familial pheochromocytoma,” 8th International Catecholamine Symposium, Asilomar, California, USA (October, 1996).
  • Invited seminar: “Cardiac sympathetic nerve function in congestive heart failure,” Clinical Research Center, Vanderbilt University, Nashville, Tennessee (February, 1997).
  • Invited seminar: “Catecholamine systems in health and disease,” Christchurch Clinical School of Medicine, Christchurch, New Zealand (March, 1997).
  • Invited lecture: “Catecholamine systems in health and disease,” Queensland Institute of Medical Technology, Brisbane, Queensland, Australia (March, 1997).
  • Invited seminar: “Plasma metanephrines: a sensitive test for detecting sporadic and familial pheochromocytoma,” Department of Endocrinology, Washington Hospital Medical Center, Washington DC (February, 1998).
  • Invited lecture: “Norepinephrine kinetics and metabolism: application to studies of the sympathetic nervous system in health and disease” C.O.E. International Symposium on Signaling in the Cardiovascular System, Osaka, Japan (March, 1998).
  • Invited seminar: “Norepinephrine kinetics and metabolism: application to studies in health and disease,” Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan (March, 1998).
  • Invited lecture: “Sources and physiological significance of plasma dopamine sulfate,” 7th International Conference on Peripheral Dopamine, Dublin, Ireland (August, 1998).
  • Invited seminar: “Understanding catecholamine metabolism as a guide to the diagnosis of pheochromocytoma” Clinical Research Center, Vanderbilt University, Nashville, Tennessee (August, 1998).
  • Invited seminar: “Plasma metanephrines: a sensitive test for detecting sporadic and familial pheochromocytoma,” Department of Endocrinology, Georgetown University, Georgetown, Washington DC (1998).
  • Invited lecture: “Plasma metanephrines: a novel and cost-effective test for pheochromocytoma.” 1st International Meeting on Adrenal Disease: Basic and Clinical Aspects. Ribeirao Preto, Brazil (September, 1999).
  • NIH Clinical Staff Conference: Recent Advances in the genetics, diagnosis, localization and treatment of pheochromocytoma. National Institutes of Health, Bethesda (September, 1999).   
  • Plenary lecture: “Cardiac sympathetic nerve function in congestive heart failure” 7th Meeting on Nuclear Cardiology, Tokyo, Japan (November, 1999).
  • Invited seminar: “Catecholamine systems in health and disease,” University of Erlangen-Nürnberg, Erlangen, Germany (December, 1999).
  • Invited lecture: “A new strategy for reliable, efficient and cost-effective biochemical diagnosis of pheochromocytoma,” 9th International Catecholamine Symposium, Kyoto, Japan (April, 2001).
  • Invited lecture: “Finding elusive pheochromocytomas,” Von Hippel-Lindau Family Alliance Meeting, Stanford University, San Francisco (June, 2001).
  • Invited lecture: “Hypernoradrenergic hypertension and pheochromocytoma: distinguishing neurochemical features and differential diagnosis,” Central Mechanisms of Cardiovascular Control: Integrative, Cellular and Molecular Aspects (Satellite Meeting of 34th IUPS), Sydney, Australia (August, 2001).
  • Invited lecture: “Distinct mutation-dependent biochemical and clinical phenotypes in familial pheochromocytoma” 11th International Symposium on Chromaffin Cell Biology. San Diego, USA (September, 2001).
  • Invited lectures: “New strategies for effective and efficient biochemical diagnosis of pheochromocytoma” and “Mutation-dependent biochemical and clinical phenotypes in familial pheochromocytoma,” General and Endocrine Grand Rounds, University of Montreal, Montreal, Canada (January, 2002).
  • Invited lecture: “Functions and clinical significance of catecholamine transporters as integral components of peripheral catecholamine systems.” 104th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Washington DC, USA (April, 2003).
  • Invited lecture: “Leaky catecholamine stores: Undue waste or a stress coping mechanism?” 8th Symposium on catecholamines and other neurotransmitters in stress, Smolenice Castle, Slovakia (June-July, 2003).
  • Invited seminar: “Biochemical diagnosis of pheochromocytoma: is it time to switch to plasma free metanephrines?” Johns Hopkin’s University School of Medicine, Baltimore, MD (September, 2003).
  • Invited lecture: “Distinct gene expression profiles in hereditary and sporadic pheochromocytoma,” workshop on Molecular differentiation of benign and malignant pheochromocytomas and neuroblastomas, Banbury Center, Cold Spring Harbor, NY (November, 2003).
  • Invited seminar: “Pheochromocytoma,” Georgetown University School of Medicine and Dentistry, Washington, DC (December, 2003).
  • Invited lecture: “Pheochromocytoma: Molecular genetics and diagnosis of an expanding spectrum of disease presentations” Surburban Hospital Grand Rounds, Bethesda, MD, (December 10, 2004).
  • Discussion leader: “A practical approach to efficient and cost-effective biochemical diagnosis of pheochromocytoma: the NIH perspective.” Presented as part of a breakout discussion session on biochemical diagnosis and tumor localization at the first International Symposium on Pheochromocytoma, Bethesda, Maryland (October 22, 2005).
  • Invited colloquium seminar: "Catecholamines: chemical messengers in health and disease," Michigan State University Chemistry Colloquium Series, Lansing, Michigan (April 13, 2006).
  • Invited seminar: "Catecholamines: chemical messengers in health and disease," University of Dresden, Departments of Medicine and Clinical Chemistry and Laboratory Medicine, Dresden, Germany (September 22, 2006).
  • Invited lecture: "Biochemical diagnosis of pheochromocytoma, with special implications for patients with SDHB mutations," presented as part of a Patient-Health Professional Interactive Conference — SDHB-related Pheochromocytoma: Recent Discoveries and Current Diagnostic and Therapeutic Approaches, NIH, Bethesda, Maryland, (September 29, 2006).
  • Invited lecture: "Endocrine hypertension: pheochromocytoma," presented as part of an FAES CME course — "A Review of Endocrinology Diagnosis and Treatment," Washington, DC (October 14, 2006).
  • Invited lecture: "Biochemical diagnosis of pheochromocytoma with special implications for patients with VHL syndrome," 7th International Symposium on VHL and Hereditary Kidney Cancers, London, Ontario, Canada (October 27, 2006).
  • Invited lecture: "Exaggerated adrenal medullary and cardiovascular responses to stress in pseudopheochromocytoma" 9th Symposium on catecholamines and other neurotransmitters in stress, Smolenice Castle, Slovakia (June, 2007).